Eli Lilly is rapidly approaching its Trulicity doomsday, but it may have a nice consolation prize in tirzepatide
As the hourglass begins to run out on blockbuster Trulicity’s US patent, Eli Lilly may find a successor in tirzepatide — its GIP and GLP-1 receptor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
